Gourzoulidis George, Kastanioti Catherine, Mavridoglou George, Kotsilieris Theodore, Voudigaris Dikaios, Tzanetakos Charalampos
Department of Business Administration and Organizations, School of Management, University of the Peloponnese, 24100 Kalamata, Greece.
Department of Accounting and Finance, School of Management, University of the Peloponnese, 24100 Kalamata, Greece.
Curr Oncol. 2025 Feb 25;32(3):130. doi: 10.3390/curroncol32030130.
This systematic literature review aimed to summarize the economic burden of lung cancer in Greece, identify current data gaps, and support the design of future real-world studies.
A systematic search of studies published in English on the cost of lung cancer was performed in MEDLINE-(PubMed), Scopus, and ScienceDirect. The databases were searched until September 2024, and records were screened based on our eligibility criteria. After conducting the initial literature search, the abstracts and full texts of the identified studies were reviewed and evaluated for inclusion based on predefined criteria. Data from the selected studies were then extracted into a standardized form and subsequently synthesized.
Seven studies were included in this review. The reported burden was sourced from hospital data and categorized as direct and indirect costs. Most studies (n = 6) reported direct costs, with one study reporting both direct and indirect costs. The total direct medical cost per patient increased from approximately EUR 16,000 in 2015 to EUR 58,974 in 2023, with drug acquisition costs being the key driver of the total direct cost. Additionally, the cost of end-of-life care during the final six months of a patient's life was estimated to range from EUR 6786 to EUR 7665 per patient, with pharmaceutical costs comprising the largest proportion of the total cost. One study also reported that indirect costs were considerably higher for patients than for family caregivers.
The economic burden of lung cancer has increased substantially over the past decade in Greece. The present systematic review emphasizes the critical need for comprehensive real-world studies on the economic burden of lung cancer in Greece. Addressing the current gaps holistically will yield invaluable insights for policymakers and stakeholders.
本系统文献综述旨在总结希腊肺癌的经济负担，识别当前的数据差距，并支持未来真实世界研究的设计。
在MEDLINE（PubMed）、Scopus和ScienceDirect数据库中对以英文发表的关于肺癌成本的研究进行系统检索。检索数据库至2024年9月，并根据我们的纳入标准筛选记录。在进行初步文献检索后，对已识别研究的摘要和全文进行审查，并根据预定义标准评估是否纳入。然后将所选研究的数据提取为标准化形式并进行综合分析。
本综述纳入了七项研究。报告的负担来源于医院数据，分为直接成本和间接成本。大多数研究（n = 6）报告了直接成本，一项研究同时报告了直接成本和间接成本。每位患者的总直接医疗成本从2015年的约16000欧元增加到2023年的58974欧元，药品采购成本是总直接成本的主要驱动因素。此外，患者生命最后六个月的临终护理成本估计为每位患者6786欧元至7665欧元，药品成本占总成本的比例最大。一项研究还报告称，患者的间接成本比家庭护理人员的间接成本高得多。
在过去十年中，希腊肺癌的经济负担大幅增加。本系统综述强调了对希腊肺癌经济负担进行全面真实世界研究的迫切需求。全面解决当前的差距将为政策制定者和利益相关者提供宝贵的见解。
